EU Flag

Glycotope GmbH is project based co-funded by the European Fund for Regional Development [EFRE].
Biopharmaceuticals Pipeline Glycotope’s mature biopharmaceuticals pipeline Find out more
Biopharmaceuticals Services Glycotope’s unique development expertise Find out more

Using world-leading glycobiology expertise to improve outcomes for patients

About
An introduction to our company and experienced leadership
Technology
Learn how we are leveraging our proprietary technologies to drive innovation
Gatipotuzumab
Our first-in-class antibody against a tumor-specific carbohydrate-protein epitope
Careers
Join us
News
21. Sep
2020
DCprime and Glycotope Sign Licensing Agreement to Advance Program Combining Cancer Vaccination and Therapeutic Antibody Platforms

DCprime and Glycotope Sign Licensing Agreement to Advance Program Combining Cancer Vaccination and Therapeutic […]

25. Mar
2019
Glycotope Expands Phase Ib Trial of Combination of Proprietary Anti-Tumor Antibodies to Include Marketed Anti-Tumor Antibodies

·         GATTO Study Extension to Evaluate Gatipotuzumab and Tomuzotuximab or         […]

See All News
Events
See All Events